Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Clay Siegall, PhD, will engage in a fireside chat on Wednesday, September 4, 2024, at 5:35 P.M. Eastern Time.
Interested parties can access the live audio webcast of this presentation through the Investor Relations section of Immunome's website at www.immunome.com. Following the live presentation, a replay of the webcast will be available for approximately 30 days.
Immunome, Inc. (Nasdaq: IMNM), un'azienda biotecnologica specializzata in terapie mirate contro il cancro, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale sulla Salute Globale di Morgan Stanley. Il presidente e CEO dell'azienda, Clay Siegall, PhD, parteciperà a una chiacchierata informale mercoledì 4 settembre 2024, alle 17:35 ora orientale.
Le parti interessate possono accedere alla webcast audio in diretta di questa presentazione attraverso la sezione Relazioni con gli Investitori del sito web di Immunome a www.immunome.com. Dopo la presentazione dal vivo, una registrazione della webcast sarà disponibile per circa 30 giorni.
Immunome, Inc. (Nasdaq: IMNM), una empresa de biotecnología especializada en terapias contra el cáncer, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El presidente y CEO de la empresa, Clay Siegall, PhD, participará en una charla informal el miércoles 4 de septiembre de 2024, a las 5:35 P.M. Hora del Este.
Las partes interesadas pueden acceder a la transmisión de audio en vivo de esta presentación a través de la sección de Relaciones con Inversores en el sitio web de Immunome en www.immunome.com. Después de la presentación en vivo, se dispondrá de una repetición de la transmisión durante aproximadamente 30 días.
Immunome, Inc. (Nasdaq: IMNM), 암 치료를 전문으로 하는 생명공학 회사가 모건 스탠리 제22회 글로벌 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Clay Siegall, PhD가 2024년 9월 4일 수요일 오후 5시 35분 동부 표준시에 화로 대화에 참여합니다.
관심 있는 당사자는 Immunome의 웹사이트의 투자자 관계 섹션을 통해 이 발표의 실시간 오디오 웹캐스트에 접근할 수 있습니다. 실시간 발표 후, 웹캐스트의 재생이 약 30일 동안 제공될 예정입니다.
Immunome, Inc. (Nasdaq: IMNM), une entreprise de biotechnologie spécialisée dans les thérapies ciblées contre le cancer, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Le président et PDG de l'entreprise, Clay Siegall, PhD, participera à une discussion informelle le mercredi 4 septembre 2024, à 17h35 heure de l'Est.
Les parties intéressées peuvent accéder à la diffusion audio en direct de cette présentation via la section Relations avec les investisseurs du site Web d'Immunome à www.immunome.com. Après la présentation en direct, un enregistrement de la diffusion sera disponible pendant environ 30 jours.
Immunome, Inc. (Nasdaq: IMNM), ein Biotechnologieunternehmen, das sich auf gezielte Krebstherapien spezialisiert hat, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley bekannt gegeben. Der Präsident und CEO des Unternehmens, Clay Siegall, PhD, wird am Mittwoch, den 4. September 2024, um 17:35 Uhr Eastern Time an einem Gespräch teilnehmen.
Interessierte Parteien können über den Bereich Investor Relations auf der Website von Immunome auf das Live-Audio-Webcast dieser Präsentation zugreifen unter www.immunome.com. Nach der Live-Präsentation wird für etwa 30 Tage eine Wiederholung des Webcasts verfügbar sein.
- None.
- None.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829122114/en/
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
When is Immunome (IMNM) presenting at the Morgan Stanley Global Healthcare Conference?
Who will be representing Immunome (IMNM) at the Morgan Stanley conference?
How can investors access Immunome's (IMNM) presentation at the Morgan Stanley conference?
How long will the replay of Immunome's (IMNM) Morgan Stanley conference presentation be available?
